Mira Pharmaceuticals (MIRA) Gains from Sales and Divestitures (2025)
Mira Pharmaceuticals' (MIRA) quarterly Gains from Sales and Divestitures came in at $625000.0 in Q4 2025, up 11.11% quarter-over-quarter from $562500.0 in Q3 2025.
Mira Pharmaceuticals (MIRA) Gains from Sales and Divestitures (2025) Analysis & Trends
Mira Pharmaceuticals has disclosed Gains from Sales and Divestitures across 1 years of filings, most recently posting $625000.0 for Q4 2025.
- Gains from Sales and Divestitures for Q4 2025 came in at $625000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $625000.0 (changed N/A YoY), and the FY2025 annual result was $625000.0, changed N/A from the prior year.
- Gains from Sales and Divestitures came in at $625000.0 for Q4 2025 at Mira Pharmaceuticals, up from $562500.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $625000.0 in Q4 2025 to a low of $250000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Mira Pharmaceuticals | 23.69 Mn | 12.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 625,000.00 |
| Dec 31, 2025 | 625,000.00 |
| Sep 30, 2025 | 562,500.00 |
| Sep 30, 2025 | 562,500.00 |
| Jun 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Mar 31, 2025 | 250,000.00 |
| Mar 31, 2025 | 250,000.00 |